FR21C1018I1 - SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO- 2-(1-HYDROXY-2-METHYLPROPANE-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE - Google Patents

SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO- 2-(1-HYDROXY-2-METHYLPROPANE-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE

Info

Publication number: FR21C1018I1
Authority: FR; France
Prior art keywords: difluorobenzo; cyclopropanecarboxamide; dioxol; dihydroxypropyl; methylpropane
Prior art date: 2010-03-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1018C

Other languages

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-25

Filing date

2021-05-14

Publication date

2021-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-05-14 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2021-07-02 Publication of FR21C1018I1 publication Critical patent/FR21C1018I1/en

2023-02-17 Application granted granted Critical

2023-02-17 Publication of FR21C1018I2 publication Critical patent/FR21C1018I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)

FR21C1018C 2010-03-25 2021-05-14 SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO- 2-(1-HYDROXY-2-METHYLPROPANE-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE Active FR21C1018I2 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US31737610P	2010-03-25	2010-03-25
US31995310P	2010-04-01	2010-04-01
US32163610P	2010-04-07	2010-04-07
US32156110P	2010-04-07	2010-04-07
EP11713134.2A EP2563778B1 (en)	2010-03-25	2011-03-25	Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
PCT/US2011/030032 WO2011119984A1 (en)	2010-03-25	2011-03-25	Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide

Publications (2)

Publication Number	Publication Date
FR21C1018I1 true FR21C1018I1 (en)	2021-07-02
FR21C1018I2 FR21C1018I2 (en)	2023-02-17

Family

ID=43903962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1018C Active FR21C1018I2 (en)	2010-03-25	2021-05-14	SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO- 2-(1-HYDROXY-2-METHYLPROPANE-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE

Country Status (26)

Country	Link
US (1)	US20110251253A1 (en)
EP (5)	EP3181561B1 (en)
JP (5)	JP5734410B2 (en)
CN (3)	CN109081804B (en)
AU (3)	AU2011230508B2 (en)
BR (1)	BR112012024338B1 (en)
CA (2)	CA2794559C (en)
CY (3)	CY1123794T1 (en)
DK (1)	DK2826776T3 (en)
ES (4)	ES2804202T3 (en)
FR (1)	FR21C1018I2 (en)
HR (2)	HRP20230661T1 (en)
HU (3)	HUE052759T2 (en)
IL (4)	IL222117B (en)
LT (2)	LT2826776T (en)
LU (1)	LUC00207I2 (en)
MX (3)	MX370904B (en)
NO (1)	NO2021021I1 (en)
NZ (3)	NZ700556A (en)
PL (2)	PL2826776T3 (en)
PT (1)	PT2826776T (en)
RS (1)	RS61314B1 (en)
RU (1)	RU2711481C2 (en)
SI (1)	SI2826776T1 (en)
SM (1)	SMT202100051T1 (en)
WO (1)	WO2011119984A1 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2537841A1 (en)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
PL2489659T3 (en)	2004-06-24	2018-06-29	Vertex Pharma	Modulators of ATP-binding cassette transporters
EP1912983B1 (en)	2005-08-11	2011-06-08	Vertex Pharmaceuticals, Inc.	Modulators of cystic fibrosis transmembrane conductance regulator
NZ567892A (en) *	2005-11-08	2010-12-24	Vertex Pharma	Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups
JP5409010B2 (en)	2005-12-28	2014-02-05	バーテックスファーマシューティカルズインコーポレイテッド	Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
JP5165586B2 (en)	2005-12-28	2013-03-21	バーテックスファーマシューティカルズインコーポレイテッド	1- (Benzo [d] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane-carboxamide derivatives and related as modulators of ATP binding cassette transporters for the treatment of cystic fibrosis Compound
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
IN2014KN02423A (en)	2006-04-07	2015-05-01	Vertex Pharma
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
NZ581259A (en)	2007-05-09	2012-07-27	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
CA2696298C (en)	2007-08-24	2016-09-06	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
PT2578571E (en)	2007-11-16	2015-11-30	Vertex Pharma	Isoquinoline modulators of atp-binding cassette transporters
DK2639224T3 (en)	2007-12-07	2016-10-17	Vertex Pharma	A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
PL2225230T3 (en)	2007-12-07	2017-08-31	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
CN101981011B (en)	2008-03-31	2014-05-07	沃泰克斯药物股份有限公司	Pyridyl derivatives as CFTR modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
AR073709A1 (en)	2008-09-29	2010-11-24	Vertex Pharma	ACID DOSE UNITS 3- (6- (1- (2,2-DIFLUOROBENZENE (D) (1,3) DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDE) -3-METHYLPIRIDIN-2-IL) BENZOIC
US8476442B2 (en)	2009-03-20	2013-07-02	Vertex Pharmaceutical Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105037334A (en)	2010-04-07	2015-11-11	弗特克斯药品有限公司	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
DK3150198T3 (en)	2010-04-07	2021-11-01	Vertex Pharma	PHARMACEUTICAL COMPOSITIONS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) -CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIODIN-2-YL) BENZOIC ACID AND ADMINISTRATION
CN105130948A (en) *	2010-04-22	2015-12-09	弗特克斯药品有限公司	Pharmaceutical compositions and administrations thereof
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
ME02650B (en)	2011-11-08	2017-06-20	Vertex Pharma	MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
US20130172375A1 (en) *	2011-12-13	2013-07-04	Hoffmann-La Roche Inc.	Pharmaceutical composition
CA2865519C (en)	2012-02-27	2018-01-02	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
KR101943490B1 (en)	2013-03-13	2019-04-17	플랫틀리 디스커버리 랩, 엘엘씨	Pyridazinone compounds and methods for the treatment of cystic fibrosis
CN104415345A (en) *	2013-08-30	2015-03-18	天津药物研究院	Multi-element compound and preparation method thereof
PL3068392T3 (en)	2013-11-12	2021-07-19	Vertex Pharmaceuticals Incorporated	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
EP3424534B1 (en)	2014-04-15	2021-06-02	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
TW202140422A (en)	2014-10-06	2021-11-01	美商維泰克斯製藥公司	Modulators of cystic fibrosis transmembrane conductance regulator
KR20170063954A (en)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
PT3212189T (en) *	2014-10-31	2020-11-12	Galapagos Nv	Substituted chromanes and method of use
CN107110831B (en)	2014-11-18	2020-02-21	弗特克斯药品有限公司	Methods for conducting high-throughput experiments with high-performance liquid chromatography
AU2015374342A1 (en)	2014-12-31	2017-07-20	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
HK1249893A1 (en)	2015-03-31	2018-11-16	Vertex Pharmaceuticals (Europe) Limited	Deuterated vx-661
CN105130949B (en) *	2015-09-02	2019-01-29	阜新奥瑞凯新材料有限公司	The preparation method of 1- (2,2- difluoro benzo [D] [1,3] dioxole -5- base) cyclopropanecarbonitrile
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (en)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Pharmaceutical composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (en)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
BR112019006213A2 (en)	2016-09-30	2019-06-18	Vertex Pharma	cystic fibrosis transmembrane conductance regulator modulator, pharmaceutical compositions, treatment methods and process for making the modulator
US10399940B2 (en) *	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
LT3551622T (en)	2016-12-09	2021-02-25	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA54105A (en)	2017-06-08	2021-09-15	Vertex Pharma	CYSTIC FIBROSIS TREATMENT METHODS
CA3068609A1 (en)	2017-07-01	2019-01-10	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20200171015A1 (en)	2017-07-17	2020-06-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3071278A1 (en)	2017-08-02	2019-02-07	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
TWI719349B (en)	2017-10-19	2021-02-21	美商維泰克斯製藥公司	Crystalline forms and compositions of cftr modulators
CN107880011B (en) *	2017-11-27	2019-08-16	山东省医学科学院药物研究所	The synthetic method of Lu Makatuo key intermediate
US20210228489A1 (en)	2017-12-04	2021-07-29	Vertex Pharmaceuticals Incorporated	Compositions for treating cystic fibrosis
WO2019113476A2 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	Pharmaceutical compositions for treating cystic fibrosis
WO2019161078A1 (en)	2018-02-15	2019-08-22	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
CN110193012B (en) *	2018-02-27	2022-02-08	江苏恒瑞医药股份有限公司	Pharmaceutical composition of oxopyridine amide derivatives and preparation method thereof
US20210139514A1 (en)	2018-04-05	2021-05-13	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20220047564A1 (en)	2018-11-14	2022-02-17	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3067611A1 (en)	2019-01-15	2020-07-15	Apotex Inc.	Processes for the preparation of tezacaftor and intermediates thereof
UY38630A (en)	2019-04-03	2020-10-30	Vertex Pharma	MODULATING AGENTS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSIS
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
US11884672B2 (en)	2019-05-14	2024-01-30	Vertex Pharmaceuticals Incorporated	Modulators of alpha-1 antitrypsin
WO2020242935A1 (en)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
IL302295A (en)	2019-08-14	2023-06-01	Vertex Pharma	Process of making cftr modulators
KR20220064366A (en)	2019-08-14	2022-05-18	버텍스 파마슈티칼스 인코포레이티드	Crystalline Forms of CFTR Modulators
TWI867024B (en)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	Modulators of cystic fibrosis transmembrane conductance regulator
NZ785044A (en)	2019-08-14	2025-10-31	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
WO2021140525A1 (en) *	2020-01-07	2021-07-15	Msn Laboratories Private Limited, R&D Center	Novel crystalline form of 1-(2,2-difluoro-2h-1,3benzo dioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide and its process for the preparation thereof
MX2022011048A (en)	2020-03-06	2022-09-19	Quim Sintetica S A	Solid forms of tezacaftor and processes for the preparation thereof.
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (en)	2020-08-07	2023-09-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
EP4196221A1 (en)	2020-08-13	2023-06-21	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
WO2022076629A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
PE20231185A1 (en)	2020-10-07	2023-08-11	Vertex Pharma	MODULATORS OF THE REGULATOR OF TRANSMEMBRANE CONDUCTANCE OF CYSTIC FIBROSIS
MX2023004073A (en)	2020-10-07	2023-07-05	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator.
US20230374038A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230365587A1 (en)	2020-10-07	2023-11-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021358512A1 (en)	2020-10-07	2023-05-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076627A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023005589A (en)	2020-11-17	2023-07-31	Vertex Pharma	Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid.
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4259139A1 (en)	2020-12-10	2023-10-18	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20250221971A1 (en)	2022-02-03	2025-07-10	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20250320226A1 (en)	2022-02-03	2025-10-16	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
AU2023218262A1 (en)	2022-02-08	2024-08-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20240457A (en)	2022-04-06	2024-12-11	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
AU2023272562A1 (en)	2022-05-16	2024-11-07	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
JP2025517322A (en)	2022-05-16	2025-06-05	バーテックスファーマシューティカルズインコーポレイテッド	How to Treat Cystic Fibrosis
MA71698A (en)	2022-08-04	2025-05-30	Vertex Pharmaceuticals Incorporated	COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES
TW202421102A (en)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	Combination of macrocyclic cftr modulators with cftr correctors and/or cftr potentiators
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
CA3267795A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
WO2025076240A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2025166342A1 (en)	2024-02-04	2025-08-07	Vertex Pharmaceuticals Incorporated	Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
EP4648753A1 (en)	2024-02-07	2025-11-19	Vertex Pharmaceuticals Incorporated	Compositions for the treatment of cftr-mediated diseases
WO2025186214A1 (en)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5994341A (en)	1993-07-19	1999-11-30	Angiogenesis Technologies, Inc.	Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
PT901786E (en) *	1997-08-11	2007-08-07	Pfizer Prod Inc	Solid pharmaceutical dispersions with enhanced bioavailability
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
NZ521192A (en) *	2000-03-09	2005-01-28	Ono Pharmaceutical Co	Indole derivatives, process for preparation of the same and use thereof
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
WO2004028480A2 (en)	2002-09-30	2004-04-08	The Regents Of The University Of California	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP2004131393A (en) *	2002-10-08	2004-04-30	Kowa Co	Easy-to-dissolve preparation
EP1601657A1 (en)	2003-03-12	2005-12-07	Vertex Pharmaceuticals Incorporated	Pyrazole modulators of atp-binding cassette transporters
PT3103800T (en)	2003-04-11	2018-07-27	Ptc Therapeutics Inc	1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
WO2004110352A2 (en)	2003-05-16	2004-12-23	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
ATE440825T1 (en)	2003-06-06	2009-09-15	Vertex Pharma	PYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
MXPA06004005A (en)	2003-10-08	2006-06-28	Vertex Pharma	Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups.
CA2545719A1 (en)	2003-11-14	2005-06-02	Vertex Pharmaceuticals Incorporated	Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
WO2005094374A2 (en)	2004-03-30	2005-10-13	The Regents Of The University Of California	Hydrazide-containing cftr inhibitor compounds and uses thereof
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP2363129A1 (en)	2004-10-13	2011-09-07	PTC Therapeutics, Inc.	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
JP5385605B2 (en)	2005-03-11	2014-01-08	バーテックスファーマシューティカルズインコーポレイテッド	ATP-binding cassette transporter modulator
BRPI0608453A2 (en)	2005-03-18	2009-12-29	Univ California	compounds having activity in the correction of mutant cftr processing and uses of these
PL2402002T3 (en)	2005-04-08	2018-11-30	Ptc Therapeutics, Inc.	Compositions comprising an 1,2,4-oxadiazole and uses thereof for treating diseases associated with a premature stop codon
CA2609392A1 (en)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
ZA200802172B (en) *	2005-08-11	2009-06-24	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
KR20080061354A (en) *	2005-08-29	2008-07-02	사노피-아벤티스 유.에스. 엘엘씨	Amorphous Solid Dispersion of 7-Chloro-N, N, 5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino [4,5-VII] indole-1-acetamide
US8314256B2 (en)	2005-10-06	2012-11-20	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
JP2009530415A (en) *	2006-03-20	2009-08-27	バーテックスファーマシューティカルズインコーポレイテッド	Pharmaceutical composition
MX2008011976A (en) *	2006-03-20	2009-04-07	Vertex Pharma	Pharmaceutical compositions.
IN2014KN02423A (en) *	2006-04-07	2015-05-01	Vertex Pharma
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
WO2008064259A2 (en) *	2006-11-21	2008-05-29	Biokey, Inc.	Solid dispersion composition comprising fluvastatin
US8227463B2 (en) *	2007-11-22	2012-07-24	Zenyaku Kogyo Kabushiki Kaisha	Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
PL2225230T3 (en) *	2007-12-07	2017-08-31	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
UA104876C2 (en) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Modulators of atp-binding cassette transporters
BRPI0823228B8 (en) *	2008-11-06	2021-05-25	Vertex Pharmaceuticals Incorporarted	atp-binding cassette modulators
JP2013508414A (en) *	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	Compositions for the treatment of cystic fibrosis and other chronic diseases
CN105130948A (en) *	2010-04-22	2015-12-09	弗特克斯药品有限公司	Pharmaceutical compositions and administrations thereof
WO2011133953A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
BR112013004443A8 (en) *	2010-08-23	2018-01-02	Vertex Pharma	(r) -1- (2,2-difluorbenzo [d] [1,3] dioxol-5-yl) -n- (1- (2,3-dihydroxypropyl) -6-fluoro-2 pharmaceutical compositions - (1-hydroxy-2-methylpropan-2-yl) -1h-indol-5-yl) cyclopropane carboxamide and administration thereof

2011
- 2011-03-25 ES ES17154840T patent/ES2804202T3/en active Active
- 2011-03-25 EP EP17154840.7A patent/EP3181561B1/en active Active
- 2011-03-25 PL PL14172991T patent/PL2826776T3/en unknown
- 2011-03-25 RS RS20210007A patent/RS61314B1/en unknown
- 2011-03-25 BR BR112012024338-1A patent/BR112012024338B1/en active IP Right Grant
- 2011-03-25 ES ES14172991T patent/ES2845449T3/en active Active
- 2011-03-25 MX MX2017001548A patent/MX370904B/en unknown
- 2011-03-25 NZ NZ700556A patent/NZ700556A/en unknown
- 2011-03-25 CN CN201810927753.5A patent/CN109081804B/en active Active
- 2011-03-25 WO PCT/US2011/030032 patent/WO2011119984A1/en not_active Ceased
- 2011-03-25 EP EP11713134.2A patent/EP2563778B1/en active Active
- 2011-03-25 HU HUE14172991A patent/HUE052759T2/en unknown
- 2011-03-25 MX MX2012011062A patent/MX347804B/en active IP Right Grant
- 2011-03-25 NZ NZ718018A patent/NZ718018A/en unknown
- 2011-03-25 CN CN201180025743.9A patent/CN102892764B/en active Active
- 2011-03-25 AU AU2011230508A patent/AU2011230508B2/en active Active
- 2011-03-25 PL PL20206423.4T patent/PL3835297T3/en unknown
- 2011-03-25 EP EP14172991.3A patent/EP2826776B1/en active Active
- 2011-03-25 CA CA2794559A patent/CA2794559C/en active Active
- 2011-03-25 US US13/072,380 patent/US20110251253A1/en not_active Abandoned
- 2011-03-25 PT PT141729913T patent/PT2826776T/en unknown
- 2011-03-25 HU HUE20206423A patent/HUE062892T2/en unknown
- 2011-03-25 CA CA3016080A patent/CA3016080C/en active Active
- 2011-03-25 JP JP2013501522A patent/JP5734410B2/en active Active
- 2011-03-25 NZ NZ602665A patent/NZ602665A/en unknown
- 2011-03-25 DK DK14172991.3T patent/DK2826776T3/en active
- 2011-03-25 SI SI201131935T patent/SI2826776T1/en unknown
- 2011-03-25 EP EP23166117.4A patent/EP4253381A3/en active Pending
- 2011-03-25 CN CN201610452877.3A patent/CN106083832A/en active Pending
- 2011-03-25 SM SM20210051T patent/SMT202100051T1/en unknown
- 2011-03-25 HR HRP20230661TT patent/HRP20230661T1/en unknown
- 2011-03-25 LT LTEP14172991.3T patent/LT2826776T/en unknown
- 2011-03-25 EP EP20206423.4A patent/EP3835297B1/en active Active
- 2011-03-25 MX MX2016001939A patent/MX345541B/en unknown
- 2011-03-25 ES ES11713134.2T patent/ES2604105T3/en active Active
- 2011-03-25 ES ES20206423T patent/ES2951520T3/en active Active
- 2011-03-25 RU RU2015153068A patent/RU2711481C2/en active
2012
- 2012-09-24 IL IL222117A patent/IL222117B/en active IP Right Grant
2015
- 2015-03-09 JP JP2015046120A patent/JP2015127334A/en active Pending
2016
- 2016-07-27 AU AU2016208341A patent/AU2016208341B2/en active Active
- 2016-10-20 JP JP2016206062A patent/JP6326570B2/en active Active
2017
- 2017-12-21 JP JP2017245323A patent/JP6913623B2/en active Active
2018
- 2018-02-15 IL IL257542A patent/IL257542B/en active IP Right Grant
- 2018-05-07 AU AU2018203149A patent/AU2018203149B2/en active Active
2019
- 2019-10-18 IL IL270047A patent/IL270047B/en unknown
2020
- 2020-03-18 JP JP2020047688A patent/JP6964702B2/en active Active
2021
- 2021-02-01 HR HRP20210165TT patent/HRP20210165T1/en unknown
- 2021-02-08 CY CY20211100108T patent/CY1123794T1/en unknown
- 2021-05-14 LT LTPA2021508C patent/LTC2826776I2/lt unknown
- 2021-05-14 FR FR21C1018C patent/FR21C1018I2/en active Active
- 2021-05-17 HU HUS2100019C patent/HUS2100019I1/en unknown
- 2021-05-18 LU LU00207C patent/LUC00207I2/en unknown
- 2021-05-19 CY CY2021014C patent/CY2021014I2/en unknown
- 2021-05-21 NO NO2021021C patent/NO2021021I1/en unknown
- 2021-11-25 IL IL288388A patent/IL288388A/en unknown
2023
- 2023-08-03 CY CY20231100390T patent/CY1126143T1/en unknown

Also Published As

Publication number	Publication date
IL288388A (en)	2022-01-01
EP2563778B1 (en)	2016-08-24
JP6964702B2 (en)	2021-11-10
CY2021014I1 (en)	2021-10-15
RU2012145295A (en)	2014-04-27
IL222117B (en)	2018-02-28
HUE062892T2 (en)	2023-12-28
EP2563778A1 (en)	2013-03-06
MX2012011062A (en)	2013-01-14
BR112012024338B1 (en)	2021-09-28
CN102892764B (en)	2016-07-06
LTPA2021508I1 (en)	2021-06-10
AU2011230508B2 (en)	2016-04-28
NZ700556A (en)	2016-04-29
DK2826776T3 (en)	2020-12-14
IL257542A (en)	2018-04-30
PT2826776T (en)	2021-02-01
CN109081804B (en)	2021-12-10
MX370904B (en)	2020-01-09
RU2711481C2 (en)	2020-01-17
EP2826776A1 (en)	2015-01-21
SMT202100051T1 (en)	2021-03-15
HRP20230661T1 (en)	2023-09-29
LT2826776T (en)	2021-01-11
JP6913623B2 (en)	2021-08-04
EP3835297C0 (en)	2023-06-07
AU2016208341A1 (en)	2016-08-18
CA2794559C (en)	2019-07-23
CY2021014I2 (en)	2021-10-15
HUS2100019I1 (en)	2021-06-28
ES2845449T3 (en)	2021-07-26
EP3181561A1 (en)	2017-06-21
AU2018203149B2 (en)	2019-07-25
IL257542B (en)	2020-05-31
CA3016080C (en)	2019-08-20
AU2016208341B2 (en)	2018-05-24
CA3016080A1 (en)	2011-09-29
HUE052759T2 (en)	2021-05-28
US20110251253A1 (en)	2011-10-13
CN102892764A (en)	2013-01-23
PL2826776T3 (en)	2021-05-31
EP4253381A2 (en)	2023-10-04
EP3181561B1 (en)	2020-05-20
HRP20210165T1 (en)	2021-03-19
RU2573830C2 (en)	2016-01-27
RU2015153068A (en)	2019-01-17
FR21C1018I2 (en)	2023-02-17
EP2826776B1 (en)	2020-11-25
JP6326570B2 (en)	2018-05-23
PL3835297T3 (en)	2023-09-11
BR112012024338A2 (en)	2020-09-01
NO2021021I1 (en)	2021-05-21
CN106083832A (en)	2016-11-09
NZ718018A (en)	2017-10-27
JP2013523655A (en)	2013-06-17
ES2951520T3 (en)	2023-10-23
EP3835297A1 (en)	2021-06-16
MX347804B (en)	2017-05-15
LUC00207I2 (en)	2024-10-04
MX345541B (en)	2017-02-03
CY1126143T1 (en)	2023-11-15
RU2015153068A3 (en)	2019-07-17
ES2804202T3 (en)	2021-02-04
EP4253381A3 (en)	2023-11-01
NZ602665A (en)	2014-10-31
WO2011119984A1 (en)	2011-09-29
AU2011230508A1 (en)	2012-10-18
ES2604105T3 (en)	2017-03-03
SI2826776T1 (en)	2021-02-26
AU2018203149A1 (en)	2018-05-24
CY1123794T1 (en)	2021-09-14
JP2015127334A (en)	2015-07-09
JP5734410B2 (en)	2015-06-17
JP2018048207A (en)	2018-03-29
RS61314B1 (en)	2021-02-26
CN109081804A (en)	2018-12-25
EP3835297B1 (en)	2023-06-07
IL270047B (en)	2022-01-01
JP2020094068A (en)	2020-06-18
JP2017008120A (en)	2017-01-12
CA2794559A1 (en)	2011-09-29
LTC2826776I2 (en)	2023-12-11

Publication	Publication Date	Title
FR21C1018I2 (en)	2023-02-17	SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO- 2-(1-HYDROXY-2-METHYLPROPANE-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE
SMT201600174B (en)	2016-08-31	SOLID FORMS OF ACID 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOSSOL-5-IL) CYCLOPROPANCARBOSSAMID) -3-METHYLPYRIDIN-2-IL) BENZOIC
BRPI0911764A2 (en)	2015-10-06	cyclic inhibitors of 11betahydroxysteroid desigrogenase 1
DOP2009000202A (en)	2009-09-15	FUSIONED ANNULAR COMPOUND AS PARTIAL AGONISTS OF PPAR-GAMMA
DE502008001391D1 (en)	2010-11-04	HETEROAROYL SUBSTITUTED SERIN AMIDE
HUE043536T2 (en)	2019-08-28	Heterocyclic compounds useful as PDK1 inhibitors
EP2248360A4 (en)	2012-01-04	DIFFERENTIATION OF TONE OF VIBRATION
PL2349132T3 (en)	2021-05-17	APPARATUS FOR THE TREATMENT OF GERD
BRPI0820689A2 (en)	2019-09-24	process of producing an indolinone derivative
EP2454227A4 (en)	2015-09-16	SYNTHESIS OF PROSTANOIDS
EP2373326A4 (en)	2012-09-05	CRYSTALLINE FORMS OF GENISTEIN
EP2632461A4 (en)	2014-04-02	ISOINDOLINONE COMPOUNDS USEFUL AS PDE INHIBITORS 10
BR112012002336A2 (en)	2016-05-31	azaheterocyclic compounds
SMT201600031B (en)	2016-02-25	HETEROCYCLIC COMPOUNDS OF PHENOSSIMETHYL
EP2268635A4 (en)	2012-02-22	HETEROCYCLIC COMPOUNDS
EP2296095A4 (en)	2011-06-01	GENERATOR OF VIDEO DESCRIPTORS
EP2383313A4 (en)	2014-06-25	INK OF MARKING
NO20090798L (en)	2010-08-20	Protection structure for protection of undersea equipment
BR112013008049A2 (en)	2016-06-21	synthesis process of beta-dicarbonylated compounds
EP2242554A4 (en)	2012-03-28	DISTRIBUTOR OF DESCENT
EP2509970A4 (en)	2013-05-08	DEPOLYMERIZATION OF OLIGOMERIC CYCLIC ETHERS
IT1394292B1 (en)	2012-06-06	PROCEDURE FOR THE SYNTHESIS OF PREGABALINA
HK40101616A (en)	2024-05-24	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
ES1069389Y (en)	2009-06-16	"DEVICE FOR CHROMATIC REPRESENTATION OF ENVIRONMENTAL SOUND"
FR2944412B1 (en)	2011-07-01	FISHING EQUIPMENT